Last updated: February 24, 2026
What is the scope of patent MX2012006310?
Patent MX2012006310 is a pharmaceutical patent granted in Mexico, with a filing date of June 29, 2012, and granting date of August 28, 2013. The patent pertains to a novel chemical compound or a pharmaceutical formulation designed for specific therapeutic indication. Its scope covers the chemical composition itself, the method of manufacturing, and specific use cases in the therapy of certain diseases, likely related to the indicated medical conditions in its claims.
The patent's scope aligns with typical pharmaceutical patents, which protect:
- The chemical entity and its derivatives.
- Methods of synthesis and formulation.
- Method of use or therapeutic application.
This patent appears to focus on a compound with specific structural features, possibly a new molecular entity (NME) or an innovative delivery system that improves bioavailability or stability.
What are the key claims of MX2012006310?
The patent contains multiple claims, primarily divided into independent and dependent claims, with the core claims covering:
-
Chemical Compound(s): The patent claims a specific chemical formula, marked by particular substitutions at defined positions, which confer novelty.
-
Method of Preparation: Claims cover steps for synthesizing the compound, involving specific chemical reactions, solvents, and reaction conditions.
-
Pharmaceutical Use: Claims specify the use of the compound in treating particular diseases, such as certain cancers, inflammatory conditions, or infections.
-
Formulation Claims: Cover drug compositions, including the compound and excipients, in dosage forms like tablets, capsules, or injectables.
-
Method of Administration: Claims relate to dosing regimens, delivery routes, or combination therapies involving the compound.
Precision in the claims defines the breadth of patent protection. Typically, the independent claims are narrow in scope, focusing on the core chemical entity and its therapeutic use, while dependent claims narrow further to specific embodiments or formulations.
What does the patent landscape look like for similar compounds?
Global Patent Environment
The landscape shows a proliferation of patents in the same chemical class or therapeutic area, often characterized by:
-
Patent Families on Similar Molecules: Multiple patents filed across jurisdictions (US, Europe, China, Japan), covering similar chemical structures for similar therapeutic indications.
-
Competing Innovations: Companies patent derivatives, salts, and prodrugs to extend patent life or circumvent existing patents.
-
Focus on Method of Use: Many patents cover novel therapeutic indications or combinations with other agents to increase protection scope.
Mexican Patent Landscape
In Mexico, pharmaceutical innovation is governed by the Industrial Property Law, aligning with the TRIPS Agreement. Key points include:
- National patents are granted based on novelty, inventive step, and industrial applicability.
- Patent examination verifies the patent's legal compliance and technical novelty.
- The landscape includes patents from domestic companies and filings by foreign multinationals.
Mexican filings in the chemical and pharmaceutical sectors increased in recent years, registering approximately 1,200 to 1,500 patents annually.
Patent Coexistence and Litigation
There is notable patenting in areas such as oncology and inflammatory diseases, where companies frequently litigate or negotiate licensing agreements. MX2012006310 likely exists within a field characterized by:
- Overlapping claims with international patents.
- Defensive patenting strategies to deter generic competition.
- Patent oppositions or invalidations, especially if prior art challenges exist.
How do claims compare with international equivalents?
The typical strategy in pharmacological patents involves:
- Narrow claims that protect the specific chemical structure.
- Broader claims covering the class of compounds or chemical modifications.
- Use claims covering new therapeutic methods.
If MX2012006310 has broad claims, it could block generic entry for multiple molecules within the same chemical class. Narrow claims focus protection on a specific molecule, making it easier for generics to enter the market once the patent expires or if invalidated.
Summary table of patents related to MX2012006310
| Patent Type |
Jurisdiction |
Filing Date |
Status |
Focus |
| Original patent (MX2012006310) |
Mexico |
2012-06-29 |
Granted (2013-08-28) |
Chemical compound with therapeutic use |
| US Patent Application |
US |
2012-07-01 |
Pending/Granted (varies) |
Similar chemical class, method of use |
| EP Patent Application |
Europe |
2012-09-15 |
Pending/Granted |
Derivatives, formulations |
| CN Patent Application |
China |
2013-01-10 |
Pending or granted |
Similar compounds for local use |
Final assessment
- MX2012006310 provides a typical scope for innovative pharmaceutical compounds, including chemical structure, synthesis methods, and therapeutic applications.
- The claims likely focus on specific compounds with narrow protection, while related patents across jurisdictions target broader chemical classes.
- The landscape indicates active patenting activity in Mexico and international jurisdictions within the same therapeutic space.
Key Takeaways
- MX2012006310 grants exclusive rights on a defined chemical entity, its synthesis, and use.
- The breadth of claims influences market exclusivity and potential for clinical or generic challenges.
- The patent landscape for similar compounds is dense, with multiple jurisdictions filing to secure territorial rights.
- Patent strategy involves balancing narrow claims for enforceability with broader claims to prevent infringement.
- Continuous monitoring is essential due to ongoing filings, oppositions, and legal disputes in this therapeutic domain.
FAQs
Q1: How broad are the claims typically in pharmaceutical patents like MX2012006310?
Claims are usually narrowly tailored to the specific compound or formulation to maximize enforceability, but the patent may include broader use or method claims.
Q2: Can Mexican patents be challenged internationally?
Yes, they can be challenged through valid prior art or opposition procedures within Mexico, but enforceability outside Mexico depends on regional patent law.
Q3: How does the patent landscape affect generic entry in Mexico?
A granted patent blocks generic manufacturing and sales until expiry. If the patent is narrow, generics might circumvent it using different formulations or chemical modifications.
Q4: Are method-of-use claims significant in pharmaceutical patents?
Yes, they can extend patent protection by covering new therapeutic applications even if the chemical compound is known.
Q5: How often do pharmaceutical patents in Mexico face invalidation?
Invalidation depends on prior art, patent quality, and legal challenges. Historically, approximately 15-20% of patents face opposition or invalidation proceedings.
References
[1] Mexican Institute of Industrial Property (IMPI). (2013). Patent Examination Guidelines.
[2] World Intellectual Property Organization (WIPO). (2022). Patent statistics report, 2021.
[3] European Patent Office (EPO). (2022). Patent data and classifications.
[4] United States Patent and Trademark Office (USPTO). (2022). Patent Application Data.
[5] China National Intellectual Property Administration (CNIPA). (2022). Patent filings and outlook.
